US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
BR112012018899A2
(pt)
*
|
2010-01-28 |
2015-09-15 |
Philadelphia Children Hospital |
"método para purificar partículas de vetor de vírus adeno-associado."
|
EP3567106A1
(en)
|
2010-04-23 |
2019-11-13 |
University of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
WO2011133874A1
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Multicistronic expression constructs
|
EP2990477B8
(en)
*
|
2011-09-08 |
2018-10-31 |
uniQure IP B.V. |
Removal of contaminating viruses from aav preparations
|
FR3002237B1
(fr)
*
|
2013-02-15 |
2017-12-15 |
Genethon |
Methodes pour la production de particules virales aav double brin
|
MX2016006774A
(es)
|
2013-11-26 |
2016-10-13 |
Us Health |
Vectores de virus adeno-asociado para el tratamiento de la enfermedad de almacenamiento de glucogeno.
|
GB201401707D0
(en)
|
2014-01-31 |
2014-03-19 |
Sec Dep For Health The |
Adeno-associated viral vectors
|
WO2015127128A2
(en)
|
2014-02-19 |
2015-08-27 |
University Of Massachusetts |
Recombinant aavs having useful transcytosis properties
|
AU2015231294B2
(en)
|
2014-03-18 |
2020-10-29 |
University Of Massachusetts |
rAAV-based compositions and methods for treating amyotrophic lateral sclerosis
|
CR20160480A
(es)
|
2014-03-21 |
2016-12-14 |
Genzyme Corp |
Terapia genetica para la retinitis pigmentaria
|
CA2946392A1
(en)
|
2014-04-25 |
2015-10-29 |
James M. Wilson |
Ldlr variants and their use in compositions for reducing cholesterol levels
|
EP3134522B1
(en)
*
|
2014-04-25 |
2021-10-06 |
University of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
WO2015187825A2
(en)
|
2014-06-03 |
2015-12-10 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
JP6842410B2
(ja)
|
2014-10-03 |
2021-03-17 |
ユニバーシティ オブ マサチューセッツ |
新規の高効率ライブラリーにより同定されるaavベクター
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
BR112017007737A2
(pt)
|
2014-10-21 |
2018-01-30 |
Univ Massachusetts |
variantes de aav recombinantes e usos das mesmas
|
KR102528156B1
(ko)
*
|
2014-11-28 |
2023-05-03 |
유니큐어 아이피 비.브이. |
파보바이러스 비리온을 포함하는 조성물 중의 dna 불순물
|
US10415044B2
(en)
|
2014-12-23 |
2019-09-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adeno-associated virus vectors encoding modified G6PC and uses thereof
|
US9862936B2
(en)
|
2015-01-13 |
2018-01-09 |
Alfa Wassermann, Inc. |
Methods of purifying adeno-associated virus (AAV) and/or recombinant adeno-associated virus (rAAV) and gradients and flow-through buffers therefore
|
EP3054006A1
(en)
|
2015-02-09 |
2016-08-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography
|
EP3054007A1
(en)
|
2015-02-09 |
2016-08-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
|
US10584321B2
(en)
|
2015-02-13 |
2020-03-10 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
US20180245073A1
(en)
*
|
2015-02-23 |
2018-08-30 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
US10058624B2
(en)
|
2015-04-16 |
2018-08-28 |
Emory University |
Recombinant promoters and vectors for protein expression in liver and use thereof
|
ES2856936T3
(es)
|
2015-04-23 |
2021-09-28 |
Univ Washington State |
Suministro del gen Smad7 como un agente terapéutico
|
CA3021949C
(en)
|
2015-04-24 |
2023-10-17 |
University Of Massachusetts |
Modified aav constructs and uses thereof
|
US11426469B2
(en)
|
2015-10-22 |
2022-08-30 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
CA3002982A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
CN105420275A
(zh)
*
|
2015-11-27 |
2016-03-23 |
中国科学院苏州生物医学工程技术研究所 |
制备外源功能基因定点整合的人神经干细胞的方法
|
WO2017100674A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav1
|
WO2017100676A1
(en)
*
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav8
|
US10889832B2
(en)
*
|
2015-12-11 |
2021-01-12 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
US11098286B2
(en)
*
|
2015-12-11 |
2021-08-24 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV9
|
ES2918998T3
(es)
|
2015-12-11 |
2022-07-21 |
Univ Pennsylvania |
Método de purificación escalable para AAVrh10
|
US11352631B2
(en)
|
2015-12-18 |
2022-06-07 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the T cell receptor
|
CA3008382A1
(en)
|
2015-12-18 |
2017-06-22 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the mhc cell receptor
|
EP3411056A4
(en)
|
2016-02-02 |
2019-10-02 |
Sangamo Therapeutics, Inc. |
COMPOUNDS FOR NETWORKING DNA BINDING DOMAINS AND SPLITTING DOMAINS
|
EP3411059A4
(en)
|
2016-02-02 |
2019-10-16 |
University Of Massachusetts |
METHOD FOR INCREASING THE EFFECTIVENESS OF THE SYSTEMIC DELIVERY OF AVV GENES TO THE CENTRAL NERVOUS SYSTEM
|
LT3411484T
(lt)
|
2016-02-05 |
2023-11-27 |
Emory University |
Viengrandžio arba sau pačiam komplementaraus adeno-asocijuoto viruso 9 injekcija į smegenų skystį
|
WO2017139643A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
PE20190434A1
(es)
*
|
2016-03-31 |
2019-03-21 |
Spark Therapeutics Inc |
PROCESO DE PRODUCCION DE rAAV A BASE DE COLUMNAS COMPLETAMENTE ESCALABLE
|
US11207426B2
(en)
|
2016-04-05 |
2021-12-28 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
GB201612248D0
(en)
|
2016-07-14 |
2016-08-31 |
Puridify Ltd |
New process
|
CA3031095A1
(en)
*
|
2016-07-21 |
2018-01-25 |
Spark Therapeutics, Inc. |
Scalable high recovery methods for producing high yield recombinant adeno-associated viral (raav) vector and recombinant adeno-associated viral (raav) vectors produced thereby
|
WO2018022511A1
(en)
|
2016-07-25 |
2018-02-01 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
CN110225975A
(zh)
|
2016-08-23 |
2019-09-10 |
阿库斯股份有限公司 |
用于治疗人受试者中非年龄相关的听力损害的组合物和方法
|
KR102572759B1
(ko)
|
2016-08-24 |
2023-08-29 |
상가모 테라퓨틱스, 인코포레이티드 |
조작된 뉴클레아제를 이용하는 유전자 발현의 조절
|
KR102455249B1
(ko)
|
2016-08-24 |
2022-10-17 |
상가모 테라퓨틱스, 인코포레이티드 |
가공된 표적 특이적 뉴클레아제
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
CN110506119A
(zh)
|
2016-10-13 |
2019-11-26 |
马萨诸塞大学 |
Aav衣壳设计
|
PT3535388T
(pt)
*
|
2016-11-04 |
2023-06-27 |
Takeda Pharmaceuticals Co |
Métodos de purificação de vírus adeno-associados
|
EP3321357A1
(en)
|
2016-11-09 |
2018-05-16 |
Deutsches Krebsforschungszentrum |
Scalable process for oncolytic rat parvovirus h-1 production and purification based on isoelectric point-based elimination of empty particles
|
WO2018140946A1
(en)
|
2017-01-30 |
2018-08-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant virus vectors for the treatment of glycogen storage disease
|
WO2018148224A1
(en)
|
2017-02-07 |
2018-08-16 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
|
EP3595688A4
(en)
|
2017-02-20 |
2020-12-30 |
The Trustees Of The University Of Pennsylvania |
GENE THERAPY TO TREAT FAMILY HYPERCHOLESTERINEMIA
|
JP7178355B2
(ja)
|
2017-02-28 |
2022-11-25 |
エンドサイト・インコーポレイテッド |
Car t細胞療法のための組成物および方法
|
JP2020519272A
(ja)
|
2017-05-09 |
2020-07-02 |
エモリー ユニバーシティー |
凝固因子変異体及びその使用
|
EP3622073A4
(en)
|
2017-05-09 |
2021-01-06 |
University of Massachusetts |
METHOD FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
US20210079422A1
(en)
*
|
2017-06-30 |
2021-03-18 |
Spark Therapeutics, Inc. |
Aav vector column purification methods
|
CN111448321A
(zh)
|
2017-09-22 |
2020-07-24 |
马萨诸塞大学 |
Sod1双表达载体及其用途
|
BR112020007790A2
(pt)
|
2017-10-20 |
2020-10-20 |
Research Institute At Nationwide Children's Hospital |
métodos e materiais para terapia genética com nt-3
|
KR20200086292A
(ko)
*
|
2017-11-08 |
2020-07-16 |
아벡시스, 인크. |
바이러스 벡터를 제조하기 위한 수단 및 방법 및 그의 용도
|
SG11202006886VA
(en)
|
2018-01-22 |
2020-08-28 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Methods of use for car t cells
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
WO2019161365A1
(en)
|
2018-02-19 |
2019-08-22 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for restoring f8 gene function and methods of use thereof
|
CA3091810A1
(en)
|
2018-03-02 |
2019-09-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of il-34 to treat retinal inflammation and neurodegeneration
|
MX2020010191A
(es)
*
|
2018-04-05 |
2021-02-26 |
Nightstarx Ltd |
Composiciones de virus adenoasociado (aav), métodos de fabricación y métodos de uso.
|
KR102627561B1
(ko)
|
2018-06-29 |
2024-01-24 |
우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 |
레버 유전성 시신경병증의 치료를 위한 조성물 및 방법
|
KR20210068014A
(ko)
|
2018-08-20 |
2021-06-08 |
우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 |
레버 유전성 시신경병증의 치료를 위한 조성물 및 방법
|
MX2021007379A
(es)
|
2018-12-18 |
2021-07-15 |
Ultragenyx Pharmaceutical Inc |
Metodos y composiciones para el tratamiento de enfermedades de almacenamiento de glucogeno.
|
FI3906066T3
(fi)
|
2019-01-04 |
2024-01-30 |
Ultragenyx Pharmaceutical Inc |
Geeniterapiakonstrukteja wilsonin taudin hoitamiseksi
|
JP7523449B2
(ja)
|
2019-01-11 |
2024-07-26 |
アクイタス セラピューティクス インコーポレイテッド |
活性剤の脂質ナノ粒子送達のための脂質
|
MA56393A
(fr)
|
2019-06-28 |
2022-05-04 |
Bayer Healthcare Llc |
Matériels et méthodes de régulation de l'édition de gènes
|
EP4004213A1
(en)
|
2019-07-25 |
2022-06-01 |
Novartis AG |
Regulatable expression systems
|
WO2021062012A1
(en)
|
2019-09-25 |
2021-04-01 |
Emory University |
Use of klk10 and engineered derivatizations thereof
|
CN113025633B
(zh)
|
2019-12-09 |
2024-08-27 |
武汉纽福斯生物科技有限公司 |
编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
|
WO2021124152A1
(en)
|
2019-12-19 |
2021-06-24 |
Pfizer Inc. |
Compositions and methods for nucleic acid transfection using cationic polymers and stabilizers
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
CA3165922A1
(en)
|
2020-01-17 |
2021-07-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Gene therapy for treatment of crx-autosomal dominant retinopathies
|
BR112022015921A2
(pt)
|
2020-02-14 |
2022-10-04 |
Ultragenyx Pharmaceutical Inc |
Terapia gênica para tratar o transtorno de deficiência de cdkl5
|
AU2021225035A1
(en)
|
2020-02-21 |
2022-10-13 |
Akouos, Inc. |
Compositions and methods for treating non-age-associated hearing impairment in a human subject
|
BR112023000327A2
(pt)
|
2020-07-16 |
2023-01-31 |
Acuitas Therapeutics Inc |
Lipídeos catiônicos para o uso em nanopartículas lipídicas
|
WO2022038164A1
(en)
|
2020-08-18 |
2022-02-24 |
Bia Separations D.O.O. |
Multimodal metal affinity processing aav capsids
|
WO2022061002A1
(en)
|
2020-09-18 |
2022-03-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
|
WO2022082017A2
(en)
*
|
2020-10-15 |
2022-04-21 |
Prevail Therapeutics, Inc. |
Recombinant adeno-associated virus compositions and methods for producing same
|
CN116348607A
(zh)
|
2020-10-15 |
2023-06-27 |
豪夫迈·罗氏有限公司 |
用于同时基因活化的核酸构建体
|
EP4229205A1
(en)
|
2020-10-15 |
2023-08-23 |
F. Hoffmann-La Roche AG |
Nucleic acid constructs for va rna transcription
|
EP4402265A1
(en)
|
2021-09-16 |
2024-07-24 |
Novartis AG |
Novel transcription factors
|
WO2023196898A1
(en)
|
2022-04-07 |
2023-10-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Beta globin mimetic peptides and their use
|
WO2023198685A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Method for determining aav genomes
|
WO2023214346A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
WO2023227438A1
(en)
|
2022-05-23 |
2023-11-30 |
F. Hoffmann-La Roche Ag |
Raman-based method for the differentiation of aav particle serotype and aav particle loading status
|
WO2023232922A1
(en)
|
2022-06-03 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant aav particles
|
WO2024013239A1
(en)
|
2022-07-14 |
2024-01-18 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant aav particles
|
WO2024056561A1
(en)
|
2022-09-12 |
2024-03-21 |
F. Hoffmann-La Roche Ag |
Method for separating full and empty aav particles
|
WO2024165456A1
(en)
|
2023-02-07 |
2024-08-15 |
F. Hoffmann-La Roche Ag |
Method for the detection of anti-aav particle antibodies
|
WO2024168358A1
(en)
|
2023-02-10 |
2024-08-15 |
Expression Therapeutics, Llc |
Lentiviral system
|
WO2024178113A1
(en)
|
2023-02-22 |
2024-08-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant adeno-associated virus vectors lacking an immunodominant t cell epitope and use thereof
|